Cannabinoid Encyclopedia

Focused research review

How does THCV affect memory, mood, and thinking?

What evidence connects THCV with neurobehavioral, cognition, mood, reward, or THC-interaction outcomes?

Updated July 2026 9 research sources Human and early research

The short answer

What is the bottom line?

Research has examined THCV and memory, mood, and thinking. This page brings together 5 human-study sources, 2 research reviews, and 2 lab, animal, or mechanism sources. The source set includes human research as well as earlier-stage studies. The studies do not all test the same product, dose, group of people, or outcome, so they cannot be reduced to one answer for every person or product. 1

Choose your next step

Want the quick path or the full picture?

Use this guide the way you need to. Start with the practical question, then open the study detail only when it helps answer something about THCV and memory, mood, and thinking.

What researchers studiedSee the main areas and the evidence behind each one. Safety and limitsKeep product, dose, medications, and context in view. Open the sourcesGo directly to the studies and references used here.

Key takeaways

What to know first

  1. 1

    Research on THCV and memory, mood, and thinking covers Neurobehavioral, cognition, mood, reward, or THC-interaction outcomes; those areas should not be combined into one claim. 1

  2. 2

    The source set includes human research as well as earlier-stage studies. 2

  3. 3

    Dose, formulation, route, study population, and outcome can change how closely a study applies to a real-world question. 3

Research areas

What researchers studied about THCV and memory, mood, and thinking

These are the main questions represented in the current literature. Each link opens a source used to build the overview.

Too limited for a firm answer

Neurobehavioral, cognition, mood, reward, or THC-interaction outcomes

This part of the literature focuses on Neurobehavioral, cognition, mood, reward, or THC-interaction outcomes. Studies may use different compounds, formulations, doses, routes, groups of people, and outcomes, so the details of each source matter. 2

How strong is the research?

Not every study answers the same question

This page separates research in people, research reviews, and earlier-stage biology before interpreting the larger question.

5 sources

Human studies

Research involving people is closest to everyday health questions. The product, dose, population, and outcome still determine what each study can show.

2 sources

Reviews and evidence summaries

Reviews can compare several studies at once. Their conclusion is only as strong and as relevant as the studies they include.

2 sources

Lab, animal, and mechanism research

Early-stage research can explain biological interest. It cannot, by itself, show that the same effect happens in people.

What these studies actually looked at

The research on THCV and memory, mood, and thinking is not one kind of study. This source set includes 4 clinical studies in people, 2 narrative or expert reviews, 1 animal study, and 1 cell or laboratory study. 3

The recorded populations or models include people or patients (5 sources), animal models (1 source), and cells or tissue models (1 source). A result from one group or model should not be assumed to apply to another. 4

The most common recorded outcome focus is neurobehavioral, cognition, mood, reward, or THC-interaction outcomes (9 sources). Closely related outcome names can still describe different measurements. 5

The THCV and memory, mood, and thinking source set also contains findings or reviews that remain too limited, indirect, or mixed for a broad answer. That uncertainty is part of the result, not an empty space to fill with assumptions. 6

Examples from the literature

What did the studies actually look at?

Each example names the research question and the study details recorded for that source.

narrative or expert review

Neuroimaging studies towards understanding the central effects of pharmacological cannabis products on patients with epilepsy.

On this page, this source examines THCV and neurobehavioral, cognition, mood, reward, or THC-interaction outcomes. 1

Study type
narrative or expert review
Population or model
people or patients
Outcome focus
neurobehavioral, cognition, mood, reward, or THC-interaction outcomes
Evidence stage
evidence still limited

narrative or expert review

Phytocannabinoids as Novel SGLT2 Modulators for Renal Glucose Reabsorption in Type 2 Diabetes Management.

On this page, this source examines THCV and neurobehavioral, cognition, mood, reward, or THC-interaction outcomes. 2

Study type
narrative or expert review
Population or model
cells or tissue models
Outcome focus
neurobehavioral, cognition, mood, reward, or THC-interaction outcomes
Evidence stage
evidence still limited

animal study

Δ8 -Tetrahydrocannabivarin has potent anti-nicotine effects in several rodent models of nicotine dependence.

On this page, this source examines THCV and neurobehavioral, cognition, mood, reward, or THC-interaction outcomes. 3

Study type
animal study
Population or model
animal models
Outcome focus
neurobehavioral, cognition, mood, reward, or THC-interaction outcomes
Evidence stage
mechanism-focused research

clinical study in people

The CB1 Neutral Antagonist Tetrahydrocannabivarin Reduces Default Mode Network and Increases Executive Control Network Resting State Functional Connectivity in Healthy Volunteers.

On this page, this source examines THCV and neurobehavioral, cognition, mood, reward, or THC-interaction outcomes. 4

Study type
clinical study in people
Population or model
people or patients
Outcome focus
neurobehavioral, cognition, mood, reward, or THC-interaction outcomes
Evidence stage
human research

clinical study in people

Medical use of cannabis. Cannabidiol: a new light for schizophrenia?

On this page, this source examines THCV and neurobehavioral, cognition, mood, reward, or THC-interaction outcomes. 5

Study type
clinical study in people
Population or model
people or patients
Outcome focus
neurobehavioral, cognition, mood, reward, or THC-interaction outcomes
Evidence stage
evidence still limited

Safety and limits

What should readers keep in mind?

Research on THCV and memory, mood, and thinking should be read beside safety. A compound can be non-intoxicating or naturally occurring and still have pharmacologic effects, side effects, interactions, or product-quality concerns. 2

Research doses are descriptions of what a study tested. They are not personal dosing instructions. Questions involving medications, pregnancy, children, driving, liver health, heart health, or serious symptoms deserve professional medical guidance.

Drug interactions Pregnancy and children Driving and impairment All safety topics

Common questions

Questions people ask

What evidence connects THCV with neurobehavioral, cognition, mood, reward, or THC-interaction outcomes?

Relevant research is collected here. The source set includes human research as well as earlier-stage studies. 7

Why is there not always a yes-or-no answer?

The sources may test different products, doses, people, and outcomes, so a single conclusion can hide important differences. 8

Where can I read the original studies?

Use the numbered citations and the source list at the bottom of the page to open PubMed or DOI records. 9

Sources

Read the research

The numbered sources below support the main overview. Links open the PubMed record or DOI in a new tab.

  1. 1
    Neuroimaging studies towards understanding the central effects of pharmacological cannabis products on patients with epilepsy. narrative or expert review; evidence still limited PubMed 28109780 DOI 10.1016/j.yebeh.2016.11.020
  2. 2
    Phytocannabinoids as Novel SGLT2 Modulators for Renal Glucose Reabsorption in Type 2 Diabetes Management. narrative or expert review; evidence still limited PubMed 40872492 DOI 10.3390/ph18081101
  3. 3
    Δ8 -Tetrahydrocannabivarin has potent anti-nicotine effects in several rodent models of nicotine dependence. animal study; mechanism-focused research PubMed 31454413 DOI 10.1111/bph.14844
  4. 4
    The CB1 Neutral Antagonist Tetrahydrocannabivarin Reduces Default Mode Network and Increases Executive Control Network Resting State Functional Connectivity in Healthy Volunteers. clinical study in people; human research PubMed 26362774 DOI 10.1093/ijnp/pyv092
  5. 5
    Medical use of cannabis. Cannabidiol: a new light for schizophrenia? clinical study in people; evidence still limited PubMed 23109356 DOI 10.1002/dta.1425
  6. 6
    Neural effects of cannabinoid CB1 neutral antagonist tetrahydrocannabivarin on food reward and aversion in healthy volunteers. clinical study in people; mechanism-focused research PubMed 25542687 DOI 10.1093/ijnp/pyu094
  7. 7
    The effect of five day dosing with THCV on THC-induced cognitive, psychological and physiological effects in healthy male human volunteers: A placebo-controlled, double-blind, crossover pilot trial. clinical study in people; mechanism-focused research PubMed 26577065 DOI 10.1177/0269881115615104
  8. 8
    Exploring Cannabis sativa L for Anti-Alzheimer Potential: An Extensive Computational Study including Molecular Docking, Molecular Dynamics, and ADMET Assessments. mechanism-focused research PubMed 40525419 DOI 10.2174/0115734064318657240822064240
  9. 9
    Molecular pathway and structural mechanism of human oncochannel TRPV6 inhibition by the phytocannabinoid tetrahydrocannabivarin. cell or laboratory study; evidence still limited PubMed 37532722 DOI 10.1038/s41467-023-40362-2
See all 9 research sources

This complete source list is the deeper research layer for the page. Study type and evidence context are shown when they are available in the current record.

  1. Phytocannabinoids as Novel SGLT2 Modulators for Renal Glucose Reabsorption in Type 2 Diabetes Management. narrative or expert review; evidence still limited / 1 linked research note PubMed 40872492
  2. Δ8 -Tetrahydrocannabivarin has potent anti-nicotine effects in several rodent models of nicotine dependence. animal study; mechanism-focused research / 1 linked research note PubMed 31454413
  3. Neural effects of cannabinoid CB1 neutral antagonist tetrahydrocannabivarin on food reward and aversion in healthy volunteers. clinical study in people; mechanism-focused research / 1 linked research note PubMed 25542687
  4. Neuroimaging studies towards understanding the central effects of pharmacological cannabis products on patients with epilepsy. narrative or expert review; evidence still limited / 1 linked research note PubMed 28109780
  5. The effect of five day dosing with THCV on THC-induced cognitive, psychological and physiological effects in healthy male human volunteers: A placebo-controlled, double-blind, crossover pilot trial. clinical study in people; mechanism-focused research / 1 linked research note PubMed 26577065
  6. Medical use of cannabis. Cannabidiol: a new light for schizophrenia? clinical study in people; evidence still limited / 1 linked research note PubMed 23109356
  7. The CB1 Neutral Antagonist Tetrahydrocannabivarin Reduces Default Mode Network and Increases Executive Control Network Resting State Functional Connectivity in Healthy Volunteers. clinical study in people; human research / 1 linked research note PubMed 26362774
  8. Molecular pathway and structural mechanism of human oncochannel TRPV6 inhibition by the phytocannabinoid tetrahydrocannabivarin. cell or laboratory study; evidence still limited / 1 linked research note PubMed 37532722
  9. Exploring Cannabis sativa L for Anti-Alzheimer Potential: An Extensive Computational Study including Molecular Docking, Molecular Dynamics, and ADMET Assessments. mechanism-focused research / 1 linked research note PubMed 40525419